Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer
Max Planck Institute for Metabolism Research · University of Cologne · +31 more institutions
Abstract
Lung cancer remains one of the leading causes of cancer-related death in developed countries. Although lung adenocarcinomas with EGFR mutations or EML4-ALK fusions respond to treatment by epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) inhibition, respectively, squamous cell lung cancer currently lacks therapeutically exploitable genetic alterations. We conducted a systematic search in a set of 232 lung cancer specimens for genetic alterations that were therapeutically amenable and then performed high-resolution gene copy number analyses. We identified frequent and focal fibroblast growth factor receptor 1 (FGFR1) amplification in squamous cell lung cancer (n = 155), but not in…
Citation impact
- FWCI
- 30.76
- Percentile
- 100%
- References
- 34
Authors
62- JMJonathan M. WeissCorresponding
Max Planck Institute for Metabolism Research
- MLMartin L. SosCorresponding
Max Planck Institute for Metabolism Research
- DSDanila SeidelCorresponding
University of Cologne, Integrated Oncology (United States), Max Planck Institute for Metabolism Research
- MPMartin Peifer
Max Planck Institute for Metabolism Research
- TZThomas Zander
University of Cologne, Integrated Oncology (United States)
Topics & keywords
- Cancer research
- Fibroblast growth factor receptor 1
- Lung cancer
- Cancer
- Biology
- Medicine
- Pathology
- Internal medicine
- Good health and well-being